A double-blind, placebo-controlled study to assess the mitochondria- targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Movement Disorders

Volumn 25, Issue 11, 2010, Pages 1670-1674

  Snow, Barry J ^a   Rolfe, Fiona L ^b   Lockhart, Michelle M ^b   Frampton, Christopher M ^c   O'Sullivan, John D ^d   Fung, Victor ^e   Smith, Robin A J ^f   Murphy, Michael P ^g   Taylor, Kenneth M ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b Antipodean Pharmaceuticals   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Mitochondria; MitoQ; Neuroprotection; Oxidative damage; PD

Indexed keywords

ANTIOXIDANT; MITOCHONDRIA TARGETED ANTIOXIDANT MITOQUINONE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MITOCHONDRION; NAUSEA; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PARKINSON DISEASE; TIME FACTORS; TREATMENT OUTCOME; UBIQUINONE;

EID: 77955792985     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23148     Document Type: Article

References (30)

1. Voss T, Ravina B. Neuroprotection in Parkinson's disease: myth or reality? Curr Neurol Neurosci Rep 2008;8:304-309.
2. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207-219.
3. Greenamyre JT, Hastings TG. Biomedicine. Parkinson's - divergent causes, convergent mechanisms. Science 2004;304:1120-1122.
4. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993;328:176-183.
5. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
6. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998;95:8892-8897.
7. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007;47:629-656.
8. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001;276:4588-4596.
9. Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 2003;100:5407-5412.
10. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. Faseb J 2005;19:1088-1095.
11. Esplugues JV, Rocha M, Nunez C, et al. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res 2006;99:1067-1075.
12. Neuzil J, Widen C, Gellert N, et al. Mitochondria transmit apoptosis signalling in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury. Redox Rep 2007;12:148-162.
13. Chandran K, Aggarwal D, Migrino RQ, et al. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 2009;96:1388-1398.
14. Boraud T, Tison F, Gross C. Quantification of motor slowness in Parkinson's disease: Correlations between the tapping test and single joint ballistic movement parameters. Parkinsonism Relat Disord 1997;3:47-50.
15. Li Y, Zhang H, Fawcett JP, Tucker IG. Quantitation and metabolism of mitoquinone, a mitochondria-targeted antioxidant, in rat by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:1958-1964.
16. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
17. Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology 1997;49:1580-1587.
18. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord 1995;10:263-266.
19. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure.The Cooperative Multicentric Group. Mov Disord 1994;9:76-83.
20. Goetz CG, Stebbins GT. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord 2004;19:1453-1456.
21. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
22. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122(Part 8):1437-1448.
23. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122(Part 8):1421-1436.
24. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Part 5):2283-2301.
25. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196-1202.
26. Gane EJ, Orr DW, Weilert F, et al. Phase II study of the mitochondrial antioxidant MitoQ for hepatitis C. J Hepatol 2008;48:S318.
27. Chandran K, Zhang J, Joseph J, et al. Neuroprotective effects of Mitochondria-targeted antioxidants against MPTP-induced oxidative damage in mitochondrial aconitase in a preclinical animal model of Parkinson's disease. In Neuroscience 2008, the Society for Neuroscience's 38th annual meeting. Washington, DC; 2008.
28. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007;6:933-938.
29. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008;70(16 Part 2):1438-1444.
30. Lowes DA, Thottakam BM, Webster NR, Murphy MP, Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med 2008;45:1559-1565.